New stock news | Haipaiker Hong Kong stock IPO prospectus invalid
Yangtuo Technology Inc. (referred to as "Haipaike") submitted its Hong Kong IPO prospectus on June 30, which expired after 6 months on December 30, with CITIC Securities being its exclusive sponsor at the time of submission.
Yangtuo Technology Inc. (referred to as Haipaike) submitted its Hong Kong IPO prospectus on June 30, which expired after 6 months on December 30, with CITIC SEC as its exclusive sponsor at the time of submission.
According to the prospectus, Haipaike is a leading trading and service platform in China, focusing on the field of home care and nutrition products. By integrating the supply chain of home care and nutrition products, the company provides enterprise customers with high-quality, considerate, stable, and reasonably priced combinations of home care and nutrition products, optimizing consumer experience and driving consumption upgrades in the lower-tier market. By 2024, the company's trading volume in the home care and nutrition products in the low-tier market in China reached 8.6 billion yuan.
According to data from Frost & Sullivan, based on the trading volume in 2024, the company has become the largest trading and service platform providing services to enterprises in the home care and nutrition products industry in China's lower-tier market, with a market share of 10.1%.
Related Articles

New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).






